SCHEMBL2339842

SCHEMBL2339842

O=C(O)c1ccc2c(c1)ncn2-c1ccccc1Br

nearest known ligand 0.70

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.70
ALDH1A1 P00352 1/20 0.70
LMNA P02545 1/20 0.70
FGFR1 P11362 5/20 0.68
NPSR1 Q6W5P4 2/20 0.55
TSHR P16473 1/20 0.55
THRB P10828 1/20 0.54
RXRA P19793 1/20 0.53
HCAR3 P49019 1/20 0.50
TP53 P04637 1/20 0.48
HTT P42858 1/20 0.47
HSD17B10 Q99714 1/20 0.47
GAA P10253 1/20 0.47
HCAR1 Q9BXC0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2345129 0.85 FGFR1 (0.70) HPGDALDH1A1LMNAFGFR1NPSR1
SCHEMBL2365060 0.84 HPGD (0.70) HPGDALDH1A1LMNAFGFR1NPSR1
SCHEMBL28288329 0.84 HPGD (0.70) HPGDALDH1A1LMNAFGFR1NPSR1
SCHEMBL122653 0.81 FGFR1 (1.00) HPGDALDH1A1LMNAFGFR1THRB
SCHEMBL30343716 0.81 FGFR1 (1.00) HPGDALDH1A1LMNAFGFR1THRB
Hydrochloric Acid SCHEMBL7986291 0.80 FGFR1 (0.97) HPGDALDH1A1LMNAFGFR1THRB
SCHEMBL2339313 0.78 HPGD (0.62) HPGDALDH1A1LMNAFGFR1NPSR1
SCHEMBL14065338 0.78 FGFR1 (0.76) HPGDALDH1A1LMNAFGFR1NPSR1
SCHEMBL2335780 0.77 FGFR1 (0.75) HPGDALDH1A1LMNAFGFR1THRB
SCHEMBL28685131 0.77 FGFR1 (0.85) HPGDALDH1A1LMNAFGFR1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831206-B1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI PHARM INC (US) 2011-08-24 EP disclosed
US-7419995-B2 N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. (US) 2008-09-02 US disclosed
EP-1831206-A2 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI Pharmaceuticals, Inc. (US) 2007-09-12 EP disclosed
WO-2006060381-A2 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI PHARMACEUTICALS, INC. (US) 2006-06-08 WO disclosed
US-20060116402-A1 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116402-A1 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library KIT, CHUK, TNNI3K HPGD 1642/4885ALDH1A1 977/4885LMNA 2471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.